| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Robert E Claypoole is President and CEO at BVS. Robert E Claypoole's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.5M at current prices.
The BVS filings lean toward selling, a net 28,786 shares.
Robert E Claypoole has 5 Form 4 filings on record from January 2024 to January 2026, all as President and CEO at Bioventus (BVS), 2024–2026.
The 12 reported transactions were 6 option or other derivative awards, 3 option exercises, 2 tax withholdings and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $262K.
The only open-market sale was 28,786 shares of BVS at an average $9.10 on January 13, 2025, about $262K. Twelve months later BVS was down 16%.